Positive top-line results from the Phase III PALOMA-2 trial
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
List view / Grid view
News
CPhI Istanbul hosts government and industry to strengthen Turkey’s role as MENA’s pharma hub
20 April 2016 | By CPhI
CPhI Istanbul 2016, organised by UBM EMEA, returns for the third consecutive year to Turkey, co-located with InnoPack, ICSE and P-MEC...
Positive Phase I results for preventive Ebola vaccine regimen
20 April 2016 | By Victoria White, Digital Content Producer
Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic...
Immuno-oncology market to hit $34 billion by 2024, says GlobalData
19 April 2016 | By Victoria White, Digital Content Producer
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, according to GlobalData...
Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
ProStrakan rebrands as Kyowa Kirin International PLC
Kyowa Hakko Kirin (KHK), the company that acquired ProStraken in 2011, has decided that its western pharmaceutical subsidiaries are to adopt the Kyowa Kirin name...
Jardiance to be investigated in chronic heart failure trials
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
Tecfidera demonstrates sustained efficacy in RRMS studies
18 April 2016 | By Victoria White, Digital Content Producer
Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
Opdivo and Yervoy combination demonstrates superior efficacy in melanoma study
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
AbbVie presents data for ABT-493 and ABT-530 regimen in HCV
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
NICE recommends ataluren for Duchenne muscular dystrophy
18 April 2016 | By Victoria White, Digital Content Producer
NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation...
Gilead announces results from two Phase III studies of TAF in HBV
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
AstraZeneca reports new data for osimertinib in NSCLC
15 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC).
Global viral infections market to hit $117.6 billion by 2021, says GBI Research
15 April 2016 | By Victoria White, Digital Content Producer
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, according to business intelligence provider GBI Research...
AbbVie presents real-world data for Viekirax + Exviera in HCV
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
